Three scientists sitting on a stage talking to an audience

Bruce Conklin (left) and Jennifer Doudna (right), along with Caribou Biosciences CEO Rachel Haurwitz (center), speaking about genome editing at a recent symposium on CRISPR at Gladstone.


The Associated Press recently reported that a researcher claims to have used the genome editing technique CRISPR-Cas9 to modify genes in two human embryos, which led to the birth of the first genetically edited babies. This work—although it has not been supported by data or a scientific publication—has caused serious concern for many researchers.

One reason is that, if accurate, it would go against an agreement reached by the scientific community in 2015 to pause such germline editing (making changes to genes that can be inherited by children).

“Patient safety is the primary concern, and it is difficult to imagine how this work could have been done safely at this time,” said Bruce Conklin, MD, genome editing expert and senior investigator at Gladstone Institutes. “It is unfortunate that the researcher seems to have proceeded when the international consensus is that experiments like this are premature.”

“Genome editing holds real promise to many patients with genetic disorders, and research into this therapeutic editing should proceed with ethical oversight.”

Bruce Conklin, MD

Jennifer Doudna, PhD, the co-inventor of CRISPR-Cas9 technology and Gladstone senior investigator, made similar remarks in a statement published by UC Berkeley, where she is a professor of chemistry and molecular and cell biology.

“It is imperative that the scientists responsible for this work fully explain their break from the global consensus that application of CRISPR-Cas9 for human germline editing should not proceed at the present time,” Doudna stated. “It is essential that this news not detract from the many important clinical efforts to use CRISPR technology to treat and cure disease in adults and in children.”

Germline editing is very different from somatic genome editing, where changes made to the genes cannot be transmitted to the next generation. The latter could offer new avenues to help patients suffering from incurable genetic conditions.

“It is particularly troubling if the recent claims distract attention from the completely valid somatic genome editing,” added Conklin, who is also a professor at UC San Francisco. “Genome editing holds real promise to many patients with genetic disorders, and research into this therapeutic editing should proceed with ethical oversight.”

As reported by WIRED magazine, Gladstone scientists are using CRISPR technology to develop a new approach coined genome surgery. This method “will use CRISPR’s molecular scissor function to remove or replace faulty genes—curing diseases at their genetic source code,” explains the article.

With recent funding from the National Institutes of Health, Conklin is also collaborating with Gladstone Senior Investigator Todd McDevitt, PhD, to study possible adverse effects of somatic cell genome editing before potential treatments are tested in human clinical trials.

Read More

Featured Experts

Support Discovery Science

Your gift to Gladstone will allow our researchers to pursue high-quality science, focus on disease, and train the next generation of scientific thought leaders.

Donate Now